HOUSTON, Feb. 13,
2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG)
("FibroBiologics"), a clinical-stage biotechnology company
focused on the development of therapeutics and potential cures for
chronic diseases using fibroblasts and fibroblast-derived materials
encompassing 150+ patents issued and pending,
presented preclinical data that employs human dermal
fibroblast (HDF) spheroids to treat an induced mouse model of
psoriasis at the 2024 Keystone Symposia for Systemic Autoimmune and
Autoinflammatory Diseases during a poster presentation. See the
poster "Exploring a Novel Cell-based Therapy Using Human Dermal
Fibroblasts in a Mouse Model of Psoriasis" here or on the
publications section of the FibroBiologics website.
"As part of our IND-enabling experiments for our early
discovery phase psoriasis project, our in vivo animal studies
have provided evidence that HDF spheroids have both external
effects on measures of psoriasis severity in addition to a direct
positive impact on reducing autoimmune inflammation," said Dr.
Hamid Khoja, Chief Scientific
Officer at FibroBiologics. "Cognizant of the high degree of
psychological and physiological impact of psoriasis on patients,
these findings indicate a potentially promising new direction for
developing cell therapy-based alternative psoriasis treatments
using fibroblast spheroids."
Psoriasis is an autoimmune inflammatory disorder often
characterized by the development of plaques and scales on the skin,
which in many individuals may lead to psoriatic arthritis.
Psoriasis affects more than eight million adults in the United States alone, and FibroBiologics is
investigating the therapeutic potential of HDFs for treating this
disorder and providing relief to patients.
In our study using an imiquimod (IMQ)-induced psoriasis
model in C57BL/6J mice, we found that a single intravenous
administration of HDF spheroids significantly reduced the severity
of psoriatic skin lesions, with a 35% decrease in average Psoriasis
Area and Severity Index (PASI) score (p<0.0001). Systemic
effects were also evident, as HDF spheroid administration
ameliorated IMQ-induced changes in spleen size and lymphocyte and
monocyte counts.
The ability of HDF spheroids to affect markers of psoriatic
inflammation was further explored by co-culturing with human
blood-derived monocytes. HDFs inhibited tumor necrosis factor
(TNF)-α and interleukin (IL)-17 production in addition to
suppressing cytokine-induced dendritic cell maturation by
down-regulating CD40, CD80, CD86, and IL-12 and up-regulating
inhibitory molecules, including IL-10, IL-1 receptor antagonist
(IL-1Ra), and programmed cell death-1 (PD-L1).
For more information, please visit FibroBiologics'
website or email FibroBiologics
at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication may contain "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning
FibroBiologics' possible or assumed future results of operations,
business strategies, debt levels, competitive position, industry
environment, potential growth opportunities and the effects of
regulation, including whether FibroBiologics will generate returns
for stockholders. These forward-looking statements are based on
FibroBiologics' management's current expectations, estimates,
projections and beliefs, as well as a number of assumptions
concerning future events. When used in this communication, the
words "estimates," "projected," "expects," "anticipates,"
"forecasts," "plans," "intends," "believes," "seeks," "may,"
"will," "should," "future," "propose" and variations of these words
or similar expressions (or the negative versions of such words or
expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future
performance, conditions or results, and involve a number of known
and unknown risks, uncertainties, assumptions and other important
factors, many of which are outside FibroBiologics' management's
control, that could cause actual results to differ materially from
the results discussed in the forward-looking statements, including
those set forth in the Risk Factors section of FibroBiologics'
Registration Statement for the Direct Offering filed with the SEC.
Copies are available on the SEC's website, www.sec.gov. These
risks, uncertainties, assumptions and other important factors
include, but are not limited to: (a) the occurrence of any event,
change or other circumstances that could cause the Registration
Statement to not become effective; (b) the ability of
FibroBiologics to continue to meet Nasdaq listing requirements; (c)
the ability to effectively manage the business as a result of the
super-voting proxy given to the Board of Directors. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and FibroBiologics assumes no obligation and, except as required by
law, does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events,
or otherwise. FibroBiologics gives no assurance that it will
achieve its expectations.
About FibroBiologics:
Based in Houston, FibroBiologics is a cell therapy,
regenerative medicine company developing a pipeline of treatments
and potential cures for chronic diseases using fibroblast cells and
fibroblast-derived materials. FibroBiologics holds 150+ US and
internationally issued patents/patents pending across various
clinical pathways, including disc degeneration, orthopedics,
multiple sclerosis, wound healing, reversing organ involution, and
cancer. FibroBiologics represents the next generation of medical
advancement in cell therapy. For more information, visit
www.FibroBiologics.com.
Investor Relations:
Nic
Johnson or Harrison Seidner,
Ph.D.
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz
Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
General Inquiries:
info@fibrobiologics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-presents-preclinical-data-at-the-2024-keystone-symposia-for-systemic-autoimmune-and-autoinflammatory-diseases-302060683.html
SOURCE FibroBiologics